Scandinavian ChemoTech AB announces outcome in rights issue
Scandinavian ChemoTech AB (publ) (“Scandinavian ChemoTech”, “ChemoTech” or the “Company”) has completed the rights issue of units, consisting of shares and warrants of series TO3, which was decided by the Board of Directors on September 21, 2022 (the “Rights Issue”). The Rights Issue has been subscribed to a total of 74.3 percent, where approximately 61.2 percent was subscribed through use of unit rights, approximately 5.6 percent was subscribed for without use of unit rights. Approximately 7.5 percent was subscribed for by top-down underwriters. APAC Equity Management, Anders Frick and